Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Roland Jäger, Heinz Gisslinger, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, Jakob Weinzierl, Fiorella Schischlik, Bettina Gisslinger, Martin Schalling, Michael Zörer, Kurt Krejcy, Christoph Klade, Robert Kralovics

Blood (2021) 137 (3): 387–391.

https://doi.org/10.1182/blood.2020005792

Published: 2021

Includes: Supplemental data

Journal Articles

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Blood (2021) 137 (2): 238–247.

https://doi.org/10.1182/blood.2020006157

Published: 2021

Includes: Supplemental data

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Blood (2019) 134 (2): 199–210.

https://doi.org/10.1182/blood.2019000519

Published: 2019

Includes: Supplemental data

Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD

Blood (2018) 132 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2018-99-119268

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms

Blood (2018) 132 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2018-99-118049

Published: 2018

Journal Articles

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Blood (2018) 132 (Supplement 1): 4.

https://doi.org/10.1182/blood-2018-99-118348

Published: 2018

Journal Articles

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood (2018) 132 (7): 694–706.

https://doi.org/10.1182/blood-2017-10-810739

Published: 2018

Includes: Supplemental data

Journal Articles

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Blood (2017) 130 (Supplement 1): 1643.

https://doi.org/10.1182/blood.V130.Suppl_1.1643.1643

Published: 2017

Journal Articles

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Martin Schalling, Andreas Gleiss, Bettina Gisslinger, Albert Wölfler, Veronika Buxhofer-Ausch, Georg Jeryczynski, MD, Maria-Theresa Krauth, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, Jurgen Thiele, Heinz Gisslinger

Blood (2017) 130 (Supplement 1): 4201.

https://doi.org/10.1182/blood.V130.Suppl_1.4201.4201

Published: 2017

Journal Articles

Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status

Blanka Kubesova, MSc, Sarka Pavlova, PhD, Jitka Malcikova, PhD, Jitka Kabathova, MSc, Lenka Radova, PhD, Nikola Tom, MSc, Boris Tichy, PhD, Karla Plevova, PhD, Barbara Kantorova, PhD, Kristyna Fiedorova, MSc, Jarmila Kissova, PhD, Bettina Gisslinger, Heinz Gisslinger, Jiri Mayer, MD, Robert Kralovics, Sarka Pospisilova, Michael Doubek

Blood (2016) 128 (22): 4284.

https://doi.org/10.1182/blood.V128.22.4284.4284

Published: 2016

Journal Articles

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Georg Jeryczynski, MD, Bettina Gisslinger, Martin Schalling, Maria Theresa Krauth, MD, Leonhard Muellauer, MD, Ana-Iris Schiefer, MD, Christoph Kornauth, MD, Ingrid Simonitsch-Klupp, MD, Jürgen Thiele, MD PhD, Heinz Gisslinger

Blood (2016) 128 (22): 4252.

https://doi.org/10.1182/blood.V128.22.4252.4252

Published: 2016

Journal Articles

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Martin Schalling, Bettina Gisslinger, Roland Jäger, PhD, Edith Bogner, Ashot S Harutyunyan, PhD, Jelena D Milosevic Feenstra, Nicole C.C. Them, Maria-Theresa Krauth, MD, Leonhard Muellauer, MD, Juergen Thiele, MD PhD, Robert Kralovics

Blood (2016) 128 (22): 1931.

https://doi.org/10.1182/blood.V128.22.1931.1931

Published: 2016

Journal Articles

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Georg Jeryczynski, MD, Albert Woelfler, MD, Bettina Gisslinger, Martin Schalling, Sonja Burgstaller, MD, Veronika Buxhofer-Ausch, Maria Theresa Krauth, MD, Klaus Geissler, MD, Ernst Schlögl, MD, Thamer Sliwa, MD, Ana-Iris Schiefer, MD, Leonhard Muellauer, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, MD, Jürgen Thiele, MDPhD, Heinz Gisslinger

Blood (2016) 128 (22): 1932.

https://doi.org/10.1182/blood.V128.22.1932.1932

Published: 2016

Journal Articles

Monitoring Molecular Response, Minimal Residual Disease and Clonal Structures in Polycythemia Vera Patients Treated with Interferon Alpha

Roland Jäger, Edith Bogner, Kerstin Trenker, Michael Gurbisz, Bettina Gisslinger, Martin Schalling, Faith Hall-Glenn, Nicole C.C. Them, Christoph Klade, Heinz Gisslinger, Gregor Hoermann, Robert Kralovics

Blood (2016) 128 (22): 1944.

https://doi.org/10.1182/blood.V128.22.1944.1944

Published: 2016

Journal Articles

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Blood (2016) 127 (3): 362–365.

https://doi.org/10.1182/blood-2015-09-668673

Published: 2016

Includes: Supplemental data

Journal Articles

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Blood (2016) 127 (3): 325–332.

https://doi.org/10.1182/blood-2015-07-661835

Published: 2016

Includes: Supplemental data

Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Blood (2015) 126 (23): 1603.

https://doi.org/10.1182/blood.V126.23.1603.1603

Published: 2015

NARROW

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Monitoring Molecular Response, Minimal Residual Disease and Clonal Structures in Polycythemia Vera Patients Treated with Interferon Alpha

Germline RBBP6 mutations in familial myeloproliferative neoplasms

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only